CA2104698A1 - Aptameres specifiques de biomolecules et methodes de production - Google Patents

Aptameres specifiques de biomolecules et methodes de production

Info

Publication number
CA2104698A1
CA2104698A1 CA002104698A CA2104698A CA2104698A1 CA 2104698 A1 CA2104698 A1 CA 2104698A1 CA 002104698 A CA002104698 A CA 002104698A CA 2104698 A CA2104698 A CA 2104698A CA 2104698 A1 CA2104698 A1 CA 2104698A1
Authority
CA
Canada
Prior art keywords
aptamer
target
oligonucleotides
oligonucleotide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002104698A
Other languages
English (en)
Inventor
John J. Toole
Linda C. Griffin
Louis C. Bock
John A. Latham
Daryl Dean Muenchau
Steven Krawczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2104698A1 publication Critical patent/CA2104698A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/332Abasic residue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/335Modified T or U
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002104698A 1991-02-21 1992-02-21 Aptameres specifiques de biomolecules et methodes de production Abandoned CA2104698A1 (fr)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US659,103 1984-10-09
US65910391A 1991-02-21 1991-02-21
US65879691A 1991-02-21 1991-02-21
US65998191A 1991-02-21 1991-02-21
US65998091A 1991-02-21 1991-02-21
US65884991A 1991-02-21 1991-02-21
US65911391A 1991-02-21 1991-02-21
US65911491A 1991-02-21 1991-02-21
US787,921 1991-02-21
US658,796 1991-02-21
US74487091A 1991-08-14 1991-08-14
US74521591A 1991-08-14 1991-08-14
US78792191A 1991-11-06 1991-11-06
US659,113 1992-02-21
US659,980 1992-02-21
US744,870 1992-02-21
US658,849 1992-02-21
US745,215 1992-02-21
US659,981 1992-02-21
US659,114 1992-02-21

Publications (1)

Publication Number Publication Date
CA2104698A1 true CA2104698A1 (fr) 1992-08-22

Family

ID=27581306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002104698A Abandoned CA2104698A1 (fr) 1991-02-21 1992-02-21 Aptameres specifiques de biomolecules et methodes de production

Country Status (6)

Country Link
EP (1) EP0572529A4 (fr)
JP (1) JPH06508022A (fr)
AU (1) AU1435492A (fr)
CA (1) CA2104698A1 (fr)
IE (1) IE920562A1 (fr)
WO (1) WO1992014843A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778432A (zh) * 2021-02-01 2021-05-11 西藏天虹科技股份有限责任公司 波棱瓜子多糖提取方法
CN115537419A (zh) * 2022-09-27 2022-12-30 福州大学 一种尿苷二磷酸的核酸适体及其筛选方法和应用

Families Citing this family (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5475096A (en) * 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5622828A (en) * 1990-06-11 1997-04-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2)
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5650275A (en) * 1990-06-11 1997-07-22 Nexstar Pharmacueticals Inc Target detection method using spectroscopically detectable nucleic acid ligands
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
WO1996034876A1 (fr) * 1995-05-04 1996-11-07 Nexstar Pharmaceuticals, Inc. Complexes de ligands d'acide nucleique
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
WO1993005184A1 (fr) * 1991-09-10 1993-03-18 Love Jack D Amplification de cibles et de signaux d'adn/arn
AU3250093A (en) 1991-12-12 1993-07-19 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
ES2257735T3 (es) * 1992-09-29 2006-08-01 Gilead Sciences, Inc. Ligandos de acido nucleico y procedimiento de produccion.
US6306598B1 (en) * 1992-11-13 2001-10-23 Regents Of The University Of California Nucleic acid-coupled colorimetric analyte detectors
US5599917A (en) * 1994-03-17 1997-02-04 Pharmagenics, Inc. Inhibition of interferon-γ with oligonucleotides
KR960704034A (ko) * 1993-07-19 1996-08-31 다니엘 엘. 캐시앙 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
JPH09506629A (ja) * 1993-12-17 1997-06-30 キュビッチョッティ,ロジャー・エス ヌクレオチドに支配された生体分子および多分子薬物の集合並びに装置
JPH09511828A (ja) * 1994-04-05 1997-11-25 ファーマジェニクス,インコーポレイテッド 化合物ライブラリー内の活性化合物の確認と識別
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US6500669B1 (en) 1994-05-04 2002-12-31 Massachusetts Institute Of Technology Programmable genotoxic agents and uses therefor
US5882941A (en) * 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US5998596A (en) * 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US5753787A (en) * 1995-04-10 1998-05-19 Yale University Nucleic acids encoding ancylostoma secreted protein
AU727460B2 (en) * 1995-05-03 2000-12-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
ATE274520T1 (de) * 1995-05-03 2004-09-15 Gilead Sciences Inc Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
JP4531132B2 (ja) 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド
EP0830368A1 (fr) 1995-06-07 1998-03-25 Genta Incorporated Nouveaux lipides cationiques a base de carbamate
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
DE69638318D1 (de) * 1995-06-07 2011-02-17 Gilead Sciences Inc Nukleinsäureliganden, die an DNA-Polymerasen binden und diese inhibieren
CA2223275A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Ligands d'acide nucleique a haute affinite pour les lectines
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
CA2223003A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Ligands de cytokines a acide nucleique et d'une affinite elevee
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
CA2630098A1 (fr) 1996-02-01 1997-08-07 Gilead Sciences, Inc. Acides nucleiques ligands a forte affinite pour les proteines du systeme complementaire
JP2000507097A (ja) * 1996-03-12 2000-06-13 ベーリンガー マンハイム ゲーエムベーハー アルギニンに結合する単離されたrna分子およびその使用
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
WO1999004800A1 (fr) * 1997-07-22 1999-02-04 Genitrix, Llc Compositions d'acides nucleiques et procedes d'introduction d'acides nucleiques dans des cellules
US6838238B1 (en) * 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
JP4276301B2 (ja) 1997-05-16 2009-06-10 エグザクト サイエンシーズ コーポレイション 固定化プローブを用いる、分子の電気泳動分析
WO1999010365A2 (fr) * 1997-08-29 1999-03-04 Gilead Sciences, Inc. Oligomeres a liaison 5',5' presentant une activite antithrombotique
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
EP1049803A4 (fr) 1997-12-15 2002-08-21 Nexstar Pharmaceuticals Inc Detection homogene de molecules cibles par interaction ligand acide nucleique et ligand balise
US5989823A (en) 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6180348B1 (en) * 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
JP3655550B2 (ja) 1998-08-14 2005-06-02 独立行政法人科学技術振興機構 Rasの標的蛋白質に特異的に結合し得る核酸
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6280943B1 (en) 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US6780850B1 (en) 1999-06-22 2004-08-24 Triumf Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
CA2403708A1 (fr) 2000-03-22 2001-09-27 Quantum Dot Corporation Procedes d'utilisation de nanocristaux semi-conducteurs dans des tests d'acides nucleiques a base de billes
US20020108130A1 (en) * 2000-05-25 2002-08-08 Asher Nathan Extracellular drug-oligonucleotides chimeric molecules
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6376190B1 (en) * 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
AU2001296305B2 (en) * 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
CA2424817A1 (fr) 2000-10-06 2002-04-11 Quantum Dot Corporation Cellules dotees d'une signature spectrale et procedes de preparation et utilisation desdites cellules
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
WO2002033116A2 (fr) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Ligands d'acides nucleiques de l'antigene membranaire prostatique specifique
US6989452B2 (en) 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
CA2456725A1 (fr) 2001-08-17 2003-02-27 Neose Technologies, Inc. Synthese chimio-enzymatique d'oligosaccharides sialyles
WO2003029492A1 (fr) * 2001-09-28 2003-04-10 Justin Gallivan Genes metaboliques et procedes et compositions associes
DK1440083T3 (da) 2001-10-25 2013-03-25 Medical Res Council Molekyler
AU2002359761A1 (en) 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
AU2003217379A1 (en) 2002-02-15 2003-09-09 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
ATE419536T1 (de) 2002-03-05 2009-01-15 Univ Texas Biospezifische kontrastmittel
NZ535602A (en) 2002-04-08 2006-07-28 Pioneer Hi Bred Int Enhanced silk exsertion under stress in Zea mays plants
WO2003093472A2 (fr) * 2002-05-06 2003-11-13 Grünenthal GmbH Acides nucleiques liant le cgrp
CA2487809A1 (fr) * 2002-06-18 2003-12-24 Archemix Corp. Molecules toxine-aptamere et procedes d'utilisation correspondants
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20040110235A1 (en) 2002-07-25 2004-06-10 David Epstein Regulated aptamer therapeutics
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
CA2502610A1 (fr) 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1597350B1 (fr) * 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Molecules d'acide nucleique, et compositions les contenant utiles dans le traitement et la detection de l'infection imputable au virus de la grippe
WO2004113495A2 (fr) 2003-05-23 2004-12-29 The President And Fellows Of Harvard College Regulateurs transcriptionnels d'arn
EP1635765B1 (fr) 2003-05-23 2013-07-17 Board Of Regents, The University Of Texas System Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1493810A1 (fr) * 2003-06-30 2005-01-05 Gentium S.p.A. Aptamères pour la cathepsine G basés sur de l'ADN
US7803624B2 (en) 2003-09-30 2010-09-28 Cytyc Corporation Automated cytological sample classification
EP1700912B1 (fr) 2003-11-22 2014-10-29 Techno Medica Co., Ltd. Methode de detection d'une molecule cible au moyen d'un aptamere
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PT2860251T (pt) 2004-02-12 2018-06-07 Archemix Llc Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
AU2005220910A1 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP1598428A1 (fr) * 2004-05-18 2005-11-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
CA2579374A1 (fr) * 2004-09-07 2006-03-30 Archemix Corp. Aptameres au facteur de von willebrand et leur utilisation en tant qu'agents therapeutiques pour des maladies thrombotiques
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
JP2008532559A (ja) 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
EP1918372A4 (fr) * 2005-07-05 2009-08-12 Ribomic Inc Acide nucléique capable de se lier à une immunoglobuline g et son utilisation
JP4910195B2 (ja) * 2005-07-05 2012-04-04 株式会社リボミック 免疫グロブリンgに結合する核酸とその利用法
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
US20080279868A1 (en) 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
WO2007059966A1 (fr) * 2005-11-23 2007-05-31 Georg Dewald Détection et traitement de l’œdème de quincke associé à un médicament
ES2622602T3 (es) 2005-12-29 2017-07-06 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
EP2952894B1 (fr) * 2006-01-17 2017-08-30 Somalogic, Inc. Trousses comprenants des aptamers
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
EP2041282B1 (fr) * 2006-07-18 2018-01-03 Noxxon Pharma AG Acides nucléiques de liaison à sdf-i
EP2089029B1 (fr) 2006-11-10 2012-10-03 Massachusetts Institute of Technology Inhibiteurs de pak pour le traitement des troubles neurodevelopementaux
JP4698559B2 (ja) * 2006-11-24 2011-06-08 Necソフト株式会社 ウサギ由来のIgG抗体に結合性を有する核酸分子
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
EP2069496A4 (fr) * 2007-07-17 2010-01-27 Somalogic Inc Selex et photoselex améliorés
WO2009015063A2 (fr) 2007-07-23 2009-01-29 Centocor Procédés et compositions pour traiter des troubles associés à une fibrose en utilisant des antagonistes de l'il-17
DE102007063902B3 (de) * 2007-08-31 2017-11-23 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
DE102007041476B4 (de) * 2007-08-31 2017-03-30 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
US8129586B2 (en) 2007-11-20 2012-03-06 Pioneer Hi-Bred International, Inc. Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants
EP2268664B1 (fr) 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Compositions doc1 et méthodes de traitement du cancer
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US20120003749A1 (en) * 2008-05-21 2012-01-05 Nec Soft, Ltd. Nucleic acid molecule capable of binding to 2,4,6-trinitrophenyl skeleton, method for detecting compound having 2,4,6-trinitrophenyl skeleton using the nucleic acid molecule, and use of the nucleic acid molecule
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
EP2326668B1 (fr) 2008-08-14 2018-01-17 Teva Pharmaceuticals Australia Pty Ltd Anticorps anti-il-12/il-23
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
WO2010093627A2 (fr) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
WO2010101818A1 (fr) 2009-03-02 2010-09-10 Pioneer Hi-Bred International, Inc. Activateurs transcriptionnels nac impliqués dans la tolérance aux stress abiotiques
KR101893011B1 (ko) 2009-04-03 2018-08-30 김성천 압타머 표적화 복합체의 제조방법
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素(hepcidin)結合之核酸類
US20100291706A1 (en) 2009-05-15 2010-11-18 Millipore Corporation Dye conjugates and methods of use
WO2011017492A2 (fr) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Nouveaux gènes eto1 et leur utilisation pour une teneur en éthylène réduite et une tolérance au stress améliorée chez les plantes
US20120295811A1 (en) * 2009-11-23 2012-11-22 Jean-Jacques Toulme Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
AU2011223527B2 (en) 2010-03-03 2014-11-13 Somalogic Operating Co., Inc. Aptamers to 4-1BB and their use in treating diseases and disorders
SG184497A1 (en) 2010-04-12 2012-11-29 Somalogic Inc 5-position modified pyrimidines and their use
WO2011132672A1 (fr) * 2010-04-19 2011-10-27 独立行政法人理化学研究所 Procédé de stabilisation des acides nucléiques fonctionnels
US20110306653A1 (en) 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
JP2012196197A (ja) * 2011-03-04 2012-10-18 Kanagawa Acad Of Sci & Technol 標的細胞表面の標的分子に特異的に結合する核酸の選択法
EP2497828A1 (fr) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Utilisation d'aptamères pour la thérapie et/ou le diagnostic des maladies auto-immunes
CN103732748A (zh) 2011-08-12 2014-04-16 塔古西库斯生物株式会社 核酸适配体的制造方法
BR112014009968A2 (pt) 2011-10-25 2017-07-04 Du Pont método para redução do teor de acetato, arabinosidase e/ou ferulato em uma planta, método de modulação da concentração de carboidratos da planta em uma planta transgénica, método para alterar o teor de acetila e de reticulação nos tecidos das plantas, método para a produção de biomassa para a produção de biocombustíveis ou silagem, produto, forragem de planta
CN103958683A (zh) * 2011-12-28 2014-07-30 希森美康株式会社 与肾上腺皮质刺激激素结合的分子及其应用
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
EP2836597A1 (fr) * 2012-04-11 2015-02-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Aptamère de métalloprotéinase matricielle 9 (mmp-9) et ses utilisations
WO2014152507A2 (fr) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Modulation de l'expression d'acc désaminase
CN105308073B (zh) 2013-06-14 2019-08-13 加利福尼亚太平洋生物科学股份有限公司 双生物素化标签
US9765375B2 (en) 2013-06-28 2017-09-19 General Electric Company Methods for developing binding-elements and uses thereof
EP4043493A1 (fr) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anticorps anti-vista et fragments
CN112410336A (zh) 2014-05-29 2021-02-26 夸克制药公司 用于预防器官中缺血再灌注损伤的方法和组合物
DE102014114834A1 (de) 2014-10-13 2016-04-14 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Nanopartikel enthaltende Polymermizellen in nicht-wässriger Lösung, Methoden zu ihrer Herstellung und ihrer Anwendung
MX2017016647A (es) 2015-06-24 2019-04-25 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista.
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
JP7468992B2 (ja) 2016-03-29 2024-04-16 ヤンセン バイオテツク,インコーポレーテツド 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
WO2017175058A1 (fr) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anticorps anti-vista et fragments de ceux-ci, leurs utilisations et leurs procédés d'identification
BR112019000693A2 (pt) 2016-07-15 2019-04-24 Poseida Therapeutics, Inc. composições de muc1- car e métodos para uso
KR20190052669A (ko) 2016-07-15 2019-05-16 포세이다 테라퓨틱스, 인크. 키메라 항원 수용체 및 사용 방법
KR20240046648A (ko) 2016-09-30 2024-04-09 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
KR20240065333A (ko) 2016-11-16 2024-05-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
KR102596343B1 (ko) * 2016-11-23 2023-10-31 베를린 큐어스 게엠베하 TLR9 활성화의 저해 및/또는 억제에 사용되는 압타머(aptamer)
EP3573658A4 (fr) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
WO2018169948A1 (fr) 2017-03-13 2018-09-20 Poseida Therapeutics, Inc. Compositions et procédés d'élimination et de remplacement sélectifs de cellules souches hématopoïétiques
KR101993427B1 (ko) * 2017-04-26 2019-10-01 주식회사 압타머사이언스 백혈구에 선택적으로 결합하는 압타머 및 이의 용도
EP3679145A2 (fr) 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Compositions et procédés d'expression génique conditionnelle médiée par un récepteur de ligand chimérique (clr)
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (fr) 2018-02-02 2019-08-08 Hammack Scott Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
CA3124103A1 (fr) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Compositions de nanotransposons et procedes d'utilisation
CN113365661A (zh) 2019-01-31 2021-09-07 新加坡科技研究局 用于治疗或预防癌症的cnx/erp57抑制剂
EP3938391A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
MA55284A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
EP3941934A4 (fr) 2019-03-18 2022-12-07 Janssen Biotech, Inc. Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
CN110172498B (zh) * 2019-04-28 2022-09-20 广东省微生物研究所(广东省微生物分析检测中心) 一种快速高效分析转录因子及其靶dna结合序列相互作用的方法
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク,インコーポレーテツド Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
AU2020289070A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibody compositions, and methods for the treatment of Psoriatic Arthritis
WO2020245677A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
EP4025593A1 (fr) 2019-09-05 2022-07-13 Poseida Therapeutics, Inc. Compositions de cellules allogéniques et procédés d'utilisation
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
MX2022012956A (es) 2020-04-14 2023-03-27 Poseida Therapeutics Inc Composiciones y métodos para su uso en el tratamiento del cáncer.
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
CN118139883A (zh) 2021-07-09 2024-06-04 詹森生物科技公司 用于生产抗tnf抗体组合物的制造方法
KR20240095537A (ko) 2021-10-04 2024-06-25 포세이다 테라퓨틱스, 인크. 트랜스포존 조성물 및 이의 이용 방법
WO2023073615A1 (fr) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
WO2023141576A1 (fr) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions et procédés d'administration d'acides nucléiques
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023223265A1 (fr) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Méthode d'évaluation et de traitement de l'arthrite psoriasique avec un anticorps il23
WO2024110898A1 (fr) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Méthode de traitement de la rectocolite hémorragique avec un anticorps spécifique anti-il23

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0689014B2 (ja) * 1986-01-21 1994-11-09 興和株式会社 トロンビン結合性物質およびその製法
US5475096A (en) * 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778432A (zh) * 2021-02-01 2021-05-11 西藏天虹科技股份有限责任公司 波棱瓜子多糖提取方法
CN112778432B (zh) * 2021-02-01 2022-04-22 西藏天虹科技股份有限责任公司 波棱瓜子多糖提取方法
CN115537419A (zh) * 2022-09-27 2022-12-30 福州大学 一种尿苷二磷酸的核酸适体及其筛选方法和应用

Also Published As

Publication number Publication date
EP0572529A1 (fr) 1993-12-08
AU1435492A (en) 1992-09-15
IE920562A1 (en) 1992-08-26
WO1992014843A1 (fr) 1992-09-03
JPH06508022A (ja) 1994-09-14
EP0572529A4 (fr) 1994-11-02

Similar Documents

Publication Publication Date Title
CA2104698A1 (fr) Aptameres specifiques de biomolecules et methodes de production
US5756291A (en) Aptamers specific for biomolecules and methods of making
WO1992014842A1 (fr) Aptameres specifiques contre la thrombine et procedes d'utilisation
Murakami et al. Role of DNA polymerase alpha and DNA primase in simian virus 40 DNA replication in vitro.
US5840867A (en) Aptamer analogs specific for biomolecules
JP4176466B2 (ja) 前立腺特異的膜抗原に対する核酸リガンド
US6369208B1 (en) Capped synthetic RNA, analogs, and aptamers
US6482594B2 (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands
Sekiguchi et al. A human enzyme that liberates uracil from DNA
AU2002224401A1 (en) Nucleic acid ligands to the prostate specific membrane antigen
JP2003506025A (ja) Cd40リガンドに対する核酸リガンド
Oravecz et al. CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV–1 strains in a T–cell line
Teebor et al. Human endonuclease activity for DNA apurinic sites
AU692185B2 (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
TW202023574A (zh) B型肝炎病毒(HBV)dsRNA劑組合物及其使用方法
EP1549763B1 (fr) Procédé de sélection d'aptamères
Sierakowska et al. Inhibition of pre-mRNA splicing by 5-fluoro-, 5-chloro-, and 5-bromouridine
Schmitz et al. Potentiation of the immune response in HIV-1+ individuals.
Jiang et al. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome
Florentz et al. Specific valylation identity of turnip yellow mosaic virus RNA by yeast valyl‐tRNA synthetase is directed by the anticodon in a kinetic rather than affinity‐based discrimination
Tomita et al. Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach
WO2001087351A1 (fr) Methode de traitement des tumeurs au moyen de ligands d'acide nucleique reactifs vis-a-vis de pdgf
Sharma et al. Purification and characterization of dolichyl-P-mannose: Man5 (GlcNAc) 2-PP-dolichol mannosyltransferase
IL307655A (en) Factor XI suppressors, preparations containing them and their uses
Wills et al. A novel in vitro model system for studying the action of ara-C

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead